Realinn Life Science Limited

Jen Cheng Lin

Chun-Chieh Lin

Jui-Chi Tsai

Yu-Ming Fan

Ying-Chi Du

Hsu-Tung Lee

The present invention relates to a novel type of PPARγ modulator having a pyrimido[5,4-d]pyrimidine main structure. The PPARγ modulator can enhance the expression and nuclear translocation of PPARγ in cells. The present invention also relates to a pharmaceutical composition comprising the PPARγ modulator of the invention encapsulated in a pharmaceutically acceptable cell-penetrating drug delivery system so that it can be directly delivered into cells. The present invention thus provides a method of preventing or treating PPARγ-related disorders or conditions comprising administering to a subject in need thereof a therapeutically effective amount of the PPARγ modulator of the invention or the pharmaceutical composition of the invention.

Compounds for enhancing PPARγ expression and nuclear translocation and therapeutic use thereof

The invention provides a method for enhancing the delivery of an anti-platelet drug for the treatment of acute stroke, comprising delivering a composition comprising an anti-platelet drug and a vehicle that can reduce the binding rate of plasma proteins, so that the anti-platelet drug can achieve the effect of treating acute stroke at a low dose. By use of the neuro-protective efficacy of anti-platelet drug, the invention allows the drug to release slowly to the site of treatment by combining anti-platelet drugs with a vehicle that can reduce the binding rate of plasma proteins to effectively reduce the dose of the anti-platelet drug and consequently reduce the side effects such as hypotension caused by administration of a high dose of the anti-platelet drugs. The invention also provides a pharmaceutical composition for enhancing treatment of acute stroke and a method for treating acute stroke using the pharmaceutical composition of the invention.

Growing community of inventors

Keelung, Taiwan

Jen Cheng Lin